Story
August 22, 2026
Moderna’s melanoma shot sparks hope, but doctors want the numbers
Moderna and Merck say their personalized mRNA therapy improved key outcomes for melanoma patients in a Phase 3 trial, sending Moderna shares higher. The result could be a landmark, but experts say the missing full data will determine how meaningful it is.
Moderna and Merck have delivered the kind of melanoma result cancer researchers have spent years chasing: a personalized mRNA treatment that appears to keep the disease from returning. The catch is that the companies have not yet shown enough data to establish how big that win really is.
On Wednesday, the partners said their Phase 3 study found that intismeran, their individualized mRNA therapy, improved recurrence-free survival and distant metastasis-free survival when combined with Merck’s Keytruda. The double-blind, placebo-controlled trial enrolled 1,137 people whose stage IIB–IV melanoma had been surgically removed; patients were assigned two-to-one to receive the combination or Keytruda alone for roughly a year.1
The treatment is designed around each patient’s tumor, encoding as many as 34 cancer-specific mutations so the immune system can recognize them as targets. That makes it a therapeutic cancer vaccine—not a preventive inoculation. “These are therapeutic, they treat cancer you already have,” said a post amplified by AI scientist Yann LeCun.
2
Investors seized on the announcement, with Moderna shares doubling after the reported success.3 The market reaction reflected both the immediate melanoma opportunity and a larger bet: that mRNA technology can move from pandemic vaccines into tailored cancer care.
Moderna and Merck point to earlier Phase 2 findings, presented in June, that showed a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. But the Phase 3 announcement supplied no comparable figures, subgroup results, quality-of-life findings or mature overall-survival data.1
That distinction is crucial. Trial leader Georgina Long called the result “a landmark moment,” while Merck research chief Dean Li said it reinforced personalized cancer treatment. Outside expert Lennard Lee was equally clear about the unresolved question: the full dataset is needed to show “precisely how large the benefit is” and which patients benefit most.1 The promise is real; proof now needs to catch up with it.